P11-11. Stable lyophilised gel vehicles for vaginal administration of recombinant C-clade HIV-1 trimeric CN54gp140

P11-11. Stable lyophilised gel vehicles for vaginal administration of recombinant C-clade HIV-1 trimeric CN54gp140

Bibliographic Details
Main Authors:	Shattock RJ, Woolfson AD, Malcolm RK, Andrews GP, Kett VL, Morrow RJ, Curran RM, Donnelly L
Format:	Article
Language:	English
Published:	BMC 2009-10-01
Series:	Retrovirology

Similar Items

P11-12. A novel vaginal ring device for the sustained delivery of recombinant C-clade HIV-1 CN54gp140
by: Shattock R, et al.
Published: (2009-10-01)

Optimising CN54gp140 plasmid delivery by comparing intramuscular and intradermal vaccination combinations with and without electroporation
by: Mann JF, et al.
Published: (2012-09-01)

Vaginal Delivery of a Recombinant HIV-1 Clade-C Trimeric gp140 within Novel Rheologically Structured Vehicles Induces Specific Immune Responses
by: Curran, R, et al.
Published: (2008)

Antigen-specific T lymphocyte responses elicited by a DNA – MVA HIV CN54gp140 immunization regime are significantly altered by the TLR4 adjuvant GLA
by: McKay PF, et al.
Published: (2012-09-01)

Phase I randomised clinical trial of an HIV-1(CN54), clade C, trimeric envelope vaccine candidate delivered vaginally.
by: David J Lewis, et al.
Published: (2011-01-01)

Rapid development of cross-clade neutralizing antibody responses after clade B gp120/gp140 protein priming and clade c gp140 protein boosting
by: Spearman P, et al.
Published: (2012-09-01)

P19-54 LB. Interrogating the membrane-proximal external region (MPER) of HIV-1 gp140
by: Van Roey G, et al.
Published: (2009-10-01)

Optimization and validation of an ELISA assay for the determination of antibody responses to CN54gp140 and AIDSVAX BE for use in the Phase IIb PrEPVacc vaccine trial.
by: Ben Gombe, et al.
Published: (2022-01-01)

Optimization and validation of an ELISA assay for the determination of antibody responses to CN54gp140 and AIDSVAX BE for use in the Phase IIb PrEPVacc vaccine trial
by: Ben Gombe, et al.
Published: (2022-01-01)

Uncleaved prefusion-optimized gp140 trimers derived from analysis of HIV-1 envelope metastability
by: Leopold Kong, et al.
Published: (2016-06-01)

A phase 1 human immunodeficiency virus vaccine trial for cross-profiling the kinetics of serum and mucosal antibody responses to CN54gp140 modulated by two homologous prime-boost vaccine regimens
by: Kratochvil, S, et al.
Published: (2017)

Inverse dose-response to gp140 YU2 foldon trimer formulated with aluminum phosphate and ISCOMATRIX® adjuvants
by: Wilson A, et al.
Published: (2012-09-01)

A Phase 1 Human Immunodeficiency Virus Vaccine Trial for Cross-Profiling the Kinetics of Serum and Mucosal Antibody Responses to CN54gp140 Modulated by Two Homologous Prime-Boost Vaccine Regimens
by: Sven Kratochvil, et al.
Published: (2017-05-01)

Stability and neutralization capacity of a novel mosaic HIV-1 gp140 trimer in a guinea pig model
by: Nkolola JP, et al.
Published: (2012-09-01)

Differential Antibody Responses to Conserved HIV-1 Neutralizing Epitopes in the Context of Multivalent Scaffolds and Native-Like gp140 Trimers
by: Charles D. Morris, et al.
Published: (2017-03-01)

Memory B cell antibodies to HIV-1 gp140 cloned from individuals infected with clade A and B viruses.
by: Hugo Mouquet, et al.
Published: (2011-01-01)

Selection of nanobodies with broad neutralizing potential against primary HIV-1 strains using soluble subtype C gp140 envelope trimers
by: Kathrin Koch, et al.
Published: (2017-08-01)

Hidden Lineage Complexity of Glycan-Dependent HIV-1 Broadly Neutralizing Antibodies Uncovered by Digital Panning and Native-Like gp140 Trimer
by: Linling He, et al.
Published: (2017-08-01)

P19-23. Putative prefusion mechanism of HIV-1 Env revealed by ligand-induced quaternary alterations in o-gp140 trimers
by: Barnett S, et al.
Published: (2009-10-01)

Hydrogel-forming microneedles prepared from "super swelling" polymers combined with lyophilised wafers for transdermal drug delivery.
by: Ryan F Donnelly, et al.
Published: (2014-01-01)

Technical transfer and commercialisation of lyophilised biopharmaceuticals — application of lyophiliser characterisation and comparability
by: Sean Cullen, et al.
Published: (2022-09-01)

Immunogenicity of HIV-1 gp140 - microbicide mixtures in mice using a vaginal delivery model
by: Wegmann, F, et al.
Published: (2007)

Christ stopped at Ephraim (John 11:54)
by: Bockmuehl, M
Published: (2024)

P05-07. Evaluation of peripheral and bone marrow B cell responses in rhesus macaques after immunization with soluble HIV-1 gp140 trimers
by: Douagi I, et al.
Published: (2009-10-01)

P19-42. Engineering, expression and antigenic and immunogenic characterization of novel soluble clade A/B heterotrimeric gp140-envelope glycoproteins
by: Stamatatos L, et al.
Published: (2009-10-01)

Intravaginal immunization using a novel antigen delivery device elicits robust vaccine antigen-specific systemic and mucosal humoral immune responses
by: McKay PF, et al.
Published: (2012-09-01)

Antiviral properties of two trimeric recombinant gp41 proteins
by: Nisole Sébastien, et al.
Published: (2006-03-01)

Germline VRC01 antibody recognition of a modified clade C HIV-1 envelope trimer and a glycosylated HIV-1 gp120 core
by: Andrew J Borst, et al.
Published: (2018-11-01)

L11S F483 (118-140) [fotograf udara]

HIV-gp140 Antigen-Adsorbed Wax Nanoparticles Induce Strong In Vivo Systemic and Mucosal Humoral Immune Responses
by: Arias, M, et al.
Published: (2008)

«Que les caigan brasas de fuego» (Sal 140,11). Comentario exegético del salmo 140
by: Wilton Gerardo Sánchez Castelblanco
Published: (2012-11-01)

Corrigendum: Immunoglobulin G1 Allotype Influences Antibody Subclass Distribution in Response to HIV gp140 Vaccination
by: Sven Kratochvil, et al.
Published: (2018-02-01)

A next-generation cleaved, soluble HIV-1 Env trimer, BG505 SOSIP.664 gp140, expresses multiple epitopes for broadly neutralizing but not non-neutralizing antibodies.
by: Rogier W Sanders, et al.
Published: (2013-09-01)

A "prime-pull" vaccine strategy has a modest effect on local and systemic antibody responses to HIV gp140 in mice.
by: John S Tregoning, et al.
Published: (2013-01-01)

Carnauba wax nanoparticles enhance strong systemic and mucosal cellular and humoral immune responses to HIV-gp140 antigen.
by: Arias, M, et al.
Published: (2011)

Transcytosis of IL-11 and Apical Redirection of gp130 Is Mediated by IL-11α Receptor
by: Niloufar Monhasery, et al.
Published: (2016-07-01)

Frequent Anti-V1V2 Responses Induced by HIV-DNA Followed by HIV-MVA with or without CN54rgp140/GLA-AF in Healthy African Volunteers
by: Frank Msafiri, et al.
Published: (2020-11-01)

Comparative immunogenicity of HIV-1 gp160, gp140 and gp120 expressed by live attenuated newcastle disease virus vector.
by: Sunil K Khattar, et al.
Published: (2013-01-01)

V2 hotspot optimized MVA vaccine expressing stabilized HIV-1 Clade C envelope Gp140 delays acquisition of heterologous Clade C Tier 2 challenges in Mamu-A*01 negative Rhesus Macaques
by: Tiffany M. Styles, et al.
Published: (2022-07-01)

P14-06. Phase 1 safety and immunogenicity randomised controlled trial of a vaginal gp140 vaccine
by: Giemza E, et al.
Published: (2009-10-01)